Liisa Bayko discusses recent news from Astria Therapeutics, Alnylam, and Akero, and comments on 89bio, Madrigal, Altimmune, and more.

What Truvian's story might say about maturation of the health tech industry today.

Margo Georgiadis describes how Montai is trying to harness anthromolecule chemistry to tackle disease.

Deborah Glasser discusses vaccines for RSV, Covid, E. coli, and more.

Dr. Agarwala gives an intro to the health tech space, describes what areas interest her, and rates the current funding environment.

Victor Bulto discusses the Inflation Reduction Act, radiotherapies, RNA approaches, and health tech.

Dr. Min describes how Cleerly’s technology is designed to improve how CT scans are analyzed.

Dr. Haut talks about demand he is seeing for Leqembi, what it means for the Alzheimer’s field, and opening the blood-brain-barrier.

Salim Syed talks about his recent initiation on CRISPR Therapeutics, and comments on Wave Life Sciences, BridgeBio, Atara, and Cytokinetics.

The head of JNJ Innovation for the east of North America talks about recent deals and JNJ’s support of science at its earliest stages.

William Blair’s Andy Hsieh discusses recent data from CymaBay, and comments on Madrigal, Viking, Exelixis, POINT, Fusion, and Icosavax.

Uli Stilz talks about the collaborating on science that might slow or reverse the progression of cardiometabolic diseases.

March Biosciences’ CEO Sarah Hein on the infrastructure available in Houston for biotech startups, and the science behind her CD5 CAR-T.

Michael Torres describes his work in Texas, co-founding ReCode, helping entrepreneurs in Houston, and founding a next-gen ADC company.

Ann Tanabe describes the institutions, facilities, funding, and people that are coming together to make Houston a competitive biotech town.

Rachel Layman and Clinton Yam talk about recent ADCs, new ways of targeting the estrogen receptor, and next-gen ADCs.

Jeff Jones describes the science behind radiopharmaceuticals and how both new targets and better isotopes are making them more effective.

Funda Meric-Bernstam describes how ADCs have improved over recent years and lists some of her favorite targets and indications.

He describes how PARP inhibitors were initial successes and where the field is going now beyond PARP with new targets.

Tyler Van Buren discusses recent news from Acelyrin and Rocket Pharma, and comments on Moderna, BridgeBio, Iovance, and Allogene.